Ambroxol was found to be safe and well tolerated in an open label trial in 18 people with Parkinson’s. It enters the brain and appears to increase levels of its chemical target GCase.
The results of a Phase II trial on the safety of nilotinib in people with Parkinson’s has shown ambiguous biochemical results and a greater number of adverse events in the treated groups.
Understanding the GDNF trial – BBC2 – 28th Feb & 7th March 2019
Call for complete characterisation of new models
Changes in messenger proteins released by neurons detected
Developing novel drugs that target multiple receptors